Has Timothy Halterman, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,503 in general payments to Timothy Halterman, MD across 96 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Timothy Halterman, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Timothy Halterman, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Timothy Halterman, MD

Gastroenterology · Reno, NVNPI 1992921316

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.3% of the total across 96 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 47.1% of the total. 2025 is the largest year on record at $1,069, 4.7 times the $225 reported in 2019. That places this record below the midpoint for gastroenterology clinicians in NV, where the typical reported total is $3,212.

$2,503in general payments, 2019–2025

Across 96 payments — averaging $26.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$1K
Aimmune Therapeutics, Inc.$153
Sanofi$152
Boston Scientific$145
Ipsen Biopharmaceuticals, Inc$141
Covidien LP$120
plus $612 from 13 others

What the payments were for

Food & beverage$2,43597%
Education$683%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	62	$1,179
Aimmune Therapeutics, Inc.	2	$153
Sanofi	6	$152
Boston Scientific	2	$145
Ipsen Biopharmaceuticals, Inc	2	$141
Covidien LP	1	$120
Gilead	1	$105
Johnson & Johnson	4	$85
AstraZeneca	1	$68
Madrigal Pharmaceuticals	2	$66
Takeda Pharmaceuticals U.S.A., Inc.	2	$59
Intercept Pharmaceuticals, Inc.	2	$39
Apollo Endosurgery US Inc	1	$38
Pfizer	2	$37
QOL Medical, LLC	1	$32
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	2	$28
Biocon Biologics Inc	1	$27
Regeneron Healthcare Solutions, Inc.	1	$14
Lilly USA, LLC	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,503 in reported general payments places this provider in the 40th percentile of 103 gastroenterology providers in Nevada.

See all gastroenterology providers in Nevada →

Medicare billing

Part B allowed, 2024

$157,707

Medicare patients

637

Services billed

1,101

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
StelaraUstekinumab	15	$404,256
Humira(Cf) PenAdalimumab	30	$298,969
XifaxanRifaximin	13	$30,279
LinzessLinaclotide	17	$16,756
Mesalamine	14	$13,100
MotegrityPrucalopride Succinate	14	$9,090
EliquisApixaban	12	$8,820
Ursodiol	50	$8,151
Dexlansoprazole DrDexlansoprazole	29	$7,400
Omeprazole	205	$2,956
Colestipol Hcl	49	$2,952
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl	135	$2,312
Pantoprazole Sodium	103	$2,138
Azathioprine	37	$1,689
Sucralfate	53	$1,466

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Johnson & JohnsonStelara	$85	$404,25615 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan	$28	$30,27913 claims
AbbVieLinzess	$1,179	$16,75617 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity	$59	$9,09014 claims
PfizerEliquis	$37	$8,82012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 103 gastroenterology providers in Nevada.

Other gastroenterology in Reno

See the full list for Nevada →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →